Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136055 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03136055 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 36 participants.
The verdict
NCT03136055, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
Interventions
- DRUG Pembrolizumab
- DRUG Paclitaxel
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-06-20 |
| Est. Completion | 2021-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136055
The ClinicalTrials.gov registry entry for NCT03136055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03136055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136055 about?
NCT03136055 is a clinical study titled "Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas". This is a pilot study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinoma
What is the current status of trial NCT03136055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-06-20. Estimated completion is 2021-10-31.
What interventions are being tested in trial NCT03136055?
The interventions under investigation include: Pembrolizumab (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT03136055?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.